Fundraising FoxEleven Biotherapeutics
Cambridge, US · Delaware corporation · 1 known investors
Find your way into Eleven Biotherapeutics
Sign up to see every warm intro you have to Eleven Biotherapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Eleven Biotherapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
DA
David A. BerryFounder
SH
Stephen HurlyExecutive
AP
Arthur P. DeCillisExecutive
GD
Gregory D. PerryExecutive
ES
Eric S. FurfineExecutive
KL
Karen L. TurbridyExecutive
Board
DS
Daniel S. LynchBoard director
AC
Abbie C. Celniker, Ph.D.Board director
CG
PG
Paul G. ChaneyBoard director
JS
Jay S. DukerBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$34.5M disclosed across 3 rounds · 2014–2018
▶$996KraisedApr 2018 · 10 investors · BiotechnologyRule 506(b)
▶$996KraisedApr 2018 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Barry J. GertzDirector
- Richard F. FitzgeraldExecutive Officer
- Leslie DanDirector
- Jane V. HendersonDirector
- Wendy L. DixonDirector
- Paul G. ChaneyDirector
- Stephen A. HurlyExecutive Officer, Director
- Abbie C. CelnikerDirector
- Jay S. DukerDirector
- Daniel S. LynchDirector
- Offering amount
- $996K
- Amount sold
- $996K
- Sales commissions
- $36.1K
- Finders' fees
- $30.9K
- Placement agents
- Laidlaw & Company (UK) Ltd.
- First sale
- Mar 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$13.5MraisedSep 2016 · 6 investors · BiotechnologyRule 506(b)
▶$13.5MraisedSep 2016 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel S. LynchDirector
- Paul G. ChaneyDirector
- Stephen HurlyExecutive Officer, Director
- John McCabeExecutive Officer
- Jay S. DukerDirector
- Wendy L. DixonDirector
- Barry J. GertzDirector
- Abbie C. Celniker, Ph.D.Director
- Leslie DanDirector
- Jane V. HendersonDirector
- Arthur P. DeCillisExecutive Officer
- Offering amount
- $13.5M
- Amount sold
- $13.5M
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$20MraisedDec 2014 · 10 investors · BiotechnologyRule 506(b)
▶$20MraisedDec 2014 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David A. BerryExecutive Officer, Director
- Gregory D. PerryExecutive Officer
- Daniel S. LynchDirector
- Eric S. FurfineExecutive Officer
- Abbie C. Celniker, Ph.D.Executive Officer, Director
- Paul ChaneyDirector
- Jane V. HendersonDirector
- Karen L. TurbridyExecutive Officer
- Cary G. PfefferDirector
- Wendy L. DixonDirector
- Offering amount
- $20M
- Amount sold
- $20M
- Sales commissions
- $1.4M
- Placement agents
- Cowen and Company, LLC, Leerink Partners LLC, Citigroup Global Markets Inc.
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Eleven Biotherapeutics went on to found or lead other companies.
Frequently asked questions
- Who founded Eleven Biotherapeutics?
- Eleven Biotherapeutics was founded by David A. Berry.
- Who are Eleven Biotherapeutics's investors?
- Eleven Biotherapeutics's investors include Third Rock Ventures.
- How much funding has Eleven Biotherapeutics raised?
- Eleven Biotherapeutics has disclosed $34.5M raised across 3 rounds.
- Where is Eleven Biotherapeutics headquartered?
- Eleven Biotherapeutics is headquartered in Cambridge, US.